---
title: "Cetuximab"
slug: "cetuximab"
date: "2023-09-15"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[regimens of treatment of metastatic colorectal cancer]]

# Cetuximab

約3%的 → 病患中報告有嚴重的 → 輸液相關效應 (罕見致命)

- 若發生嚴重輸液相關效應，必須立即且永久地停止使用cetuximab
- 此外，接受含有cetuximab的 → 輻射療法且患有頭頸部鱗狀細胞癌的 → 病患中有2%報告心肺停止和/或突然死亡
- 在cetuximab治療期間及之後必須密切監控血清電解質 (包括 ≡ 鎂，鉀，和鈣) 。

- Initial cetuximab dose of 400 mg/m2, followed by 250 mg/m2 once weekly until disease progression or unacceptable toxicity occurs.
  - Colorectal cancer, metastatic, KRAS-wild type, EGFR expressing: Cetuximab single agent therapy or in combination with irinotecan or FOLFIRI (irinotecan, fluorouracil, and leucovorin): Note: When given in combination with irinotecan or FOLFIRI, complete cetuximab dose 1 hour prior to chemotherapy.
  - Weekly dosing:
  - Initial loading dose: IV: 400 mg/m2 infused over 120 minutes.
  - Maintenance dose: IV: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity.
  - Biweekly dosing:
    - Initial and subsequent doses: IV: 500 mg/m2 infused over 120 minutes once every 2 weeks until disease progression or unacceptable toxicity.
  - Acneiform eruption (87%), changes in nails (31%), desquamation (≤95%), pruritus (16% to 47%), radiodermatitis (86%), skin rash (≤95%), xeroderma (57%)
  - Endocrine & metabolic: Dehydration (13% to 25%), hypomagnesemia (55%), wt loss (84%)
  - 

[[cetuximab vs panitumumab]]
